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Abstract
Objective To assess the cost effectiveness of different screening
strategies for abdominal aortic aneurysm in men, from the perspective
of a national health service.
Setting Screening units at regional hospitals.
Participants Hypothetical cohort of 65 year old men from the general
population.
Main outcome measures Costs (£ in 2010) and effect on health
outcomes (quality adjusted life years (QALYs)).
Results Screening seems to be highly cost effective compared with not
screening. The model estimated a 92% probability that some form of
screening would be cost effective at a threshold of £20 000 (€24 790;
$31 460). If men with an aortic diameter of 25-29 mm at the initial
screening were rescreened once after five years, 452 men per 100 000
initially screened would benefit from early detection, whereas lifetime
rescreening every five years would detect 794 men per 100 000. We
estimated the associated incremental cost effectiveness ratios for
rescreening once and lifetime rescreening to be £10 013 and £29 680
per QALY, respectively. The individual probability of being the most cost
effective strategy was higher for each rescreening strategy than for the
screening once strategy (in view of the £20 000 threshold).
Conclusions This study confirms the cost effectiveness of screening
versus no screening and lends further support to considerations of
rescreening men at least once for abdominal aortic aneurysm.
Introduction
Screening for abdominal aortic aneurysms has been the subject
of intensive focus over the past two decades. It is a classic
example of a scenario that seems to satisfy the World Health
Organisation screening criteria, becausemortality can be reduced
if a simple test is performed.1 Long term follow-up data from
large randomised controlled trials have established that screening
in men older than 65 years can reduce mortality related to
abdominal aortic aneurysm by about 50%.2 3 Also, from the
ethical perspective, this form of screening offers a clear balance
of good over harm.4
Several studies have attempted to extrapolate the benefits and
costs of screening to a lifetime perspective using decision
analytical models. These studies show a highly efficacious and
cost effective technology from the healthcare system
perspective.5-10 The most recent studies have been critically
appraised in a systematic review.11 With one or two exceptions,
the review noted that the studies had some limitations with
respect to the way the natural history of disease was modelled.
Furthermore, the results seemed to be driven by very few
original studies; for example, the growth and rupture rates from
the Multicentre Aneurysm Screening Study12 are used in most
models. There are good reasons for the adoption of these rates,
since this trial seemed to be a unique, well conducted and high
quality study. Nevertheless, if the context or the way we see the
biological disease process changes over time, these estimates
could ultimately have a date of expiry.
Over the past two decades, the practice of primary and secondary
prevention for cardiovascular disease has improved
substantially.13 The extent to which such contextual changes
affect the efficacy of screening is controversial, as noted by a
recent clinical review.14 This review suggested that smoking
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cessation had a role in the prevalence of abdominal aortic
aneurysms; however, it noted that there is currently no definitive
evidence on the effect of statins, antihypertensive drugs, and β
blockers. Although the optimal medical management thus
remains unclear, does the efficacy of screening in a context
without modern regimens for cardiovascular disease prevention
hold true today?
The emergence of additional non-pharmaceutical technologies
is also likely to have influenced the efficacy of screening. For
example, if the rate of incidental detection of aneurysms
increases, it subsequently reduces the number of undetected
cases and thereby the rationale for screening. The use of
ultrasonography, computed tomography, andmagnetic resonance
imaging has increased markedly over recent years.15
Furthermore, endovascular aorta repair has been rapidly
emerging, which has probably influenced the costs of detected
aneurysms and possibly the outcomes.16
Previous decision models seem to be in complete agreement
regarding the optimal form of screening being a one-off scan.
However, no model has examined the additional benefit of
rescreening individuals with an aortic diameter that approaches
the aneurysmal threshold. Recent evidence suggests that these
cases have the potential to grow, which would seem to justify
rescreening.17 Furthermore, it has long been recognised that
aneurysm growth and rupture rates increase exponentially with
the size of the aneurysm.18 This exponential increase contrasts
with the existing literature, which presents the disease process
as a three step model, in which all aneurysms larger than the
surgical threshold size are assumed to have equal growth and
rupture rates.
In England, a phased implementation of a national screening
programme began in March 2009, and national programme
coverage is anticipated by March 2013.19 A similar plan has
been enacted in Scotland, where implementation will commence
in autumn 2012.20 The current policy discussion in England and
Scotland thus concerns the cost effectiveness of additional
rescreening in adjunct to the programmes already being
implemented. In many other European countries, a national
decision on population screening has not been issued, and the
relevant policy debate relates to the cost effectiveness of the
optimal form of population screening (with or without
rescreening) in a modern day context.
We aimed to assess the expected lifetime costs and benefits of
four abdominal aortic aneurysm screening strategies from the
perspective of a national health service: no screening, once per
lifetime screening, twice per lifetime screening with a five year
interval, and lifetime screening every five years. In addition to
the evaluation of rescreening strategies, we considered a detailed
disease process; used the most recent parameter estimates
available or original analyses of the Danish vascular registry
and a new Danish screening trial21; included the endovascular
aortic repair technique; and used microsimulation for detailed
epidemiological results of key events, in particular the
consequences of rescreening.
Methods
Themodel evaluated a hypothetical cohort of 100 000men aged
65 years from the general population. We assigned men to one
of the four strategies, and recorded relevant events during their
lifetime to estimate the expected costs and quality adjusted life
years (QALYs). In addition to this summary, the interventions
and methods are described in detail in a technical report.22
Model strategies
We specified two baseline comparisons: no screening, after
which follow-up and elective surgery occurred only after
incidental detection; and once per lifetime screening, after which
individuals were offered screening the year they turned 65 years
old. We specified two scenarios of additional rescreening for
men with an aortic diameter at 25-29mm at the initial screening:
rescreening once after five years and rescreening every five
years for lifetime, unless an aneurysm was detected and they
were referred for follow-up or surgical evaluation.
An abdominal aortic aneurysmwas defined as an aortic diameter
of at least 30 mm, and indication for elective surgery was
defined as an aortic diameter of at least 55 mm with no
contraindications. These definitions were common among all
strategies. Detected aneurysms smaller than the threshold for
referral to elective surgery were followed at annual (30-49mm)
or biannual (50-54 mm) intervals. If a patient had an aneurysm
of at least 55 mm in aortic diameter and was unfit for surgery,
no further action was taken unless the patient became
symptomatic or rupture occurred.
Model structure
The figure⇓ details the model structure. Overall, individuals
begin in one of eight starting states according to their aortic
diameter (along the left side of the figure), and then reside or
move to subsequent states during so called Markov cycles.
Transitions were determined from probabilities of disease states,
and after a number of cycles equivalent to the expected
remaining lifespan of a 65 year old man, all individuals end up
in the dead state.
We made several simplifying assumptions to maintain
transparency. The most important assumptions, although
supported from biological evidence, were that aortic diameters
of 0-24 mm never become aneurysmal, symptoms and ruptures
never occur for aneurysms smaller than 50 mm in aortic
diameter, and that relapse never occurs. Incidental detection of
asymptomatic aneurysms occurred in all scenarios (with or
without screening) and the model acknowledged this incidental
detection. In addition to ruptures, patients with symptomatic
aneurysms were immediately referred to acute surgery. This
immediate referral reduced the potential for early detection only
to those cases that were not incidentally detected and to patients
who did not develop symptoms or rupture before they were
invited to screening. Lastly, we assumed that elective surgery
was provided without significant waiting time.
Model parameters
The model needed the following categories of parameter
estimates related to the disease process: prevalence, growth
rates, symptom rates, rupture rates, excess mortality due to
non-aneurysm related causes, and mortality rates after rupture
and surgical treatment. Apart from rupture rates reported by a
systematic review that identified two key references,23 24
parameter estimates were the result of original analyses
composed of a combination of research registries from two
Danish screening trials,2 21 the Danish vascular registry, and
national registries for causes of death. We determined general
population mortality from the most recent national statistics,
and quality of life from a representative Danish population
survey.25
We adapted attendance rates and unit costs from previously
reported microcosting studies for Denmark.2 26 The effects of
screening were adjusted according to two meta-analyses that
concluded that screening marginally reduces non-aneurysm
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related mortality and mortality after elective surgery.22 27 We
reanalysed non-aneurysm related mortality for this study to
avoid double counting aneurysm related mortality. Table 1⇓
lists all parameter estimates.
Base case analysis
Input parameters were entered into the model as probability
distributions, to reflect the uncertainty surrounding the mean
estimates. A cycle length of six months was specified. We used
microsimulation of 100 000 individuals to provide detailed
epidemiological results for each of the strategies. Count
variables (trackers) were defined and used to count the number
of key events during lifetime simulations such as detection,
symptoms, rupture, and death. We also used the trackers to
validate the model against trial observations2 and general
evidence for the biological process, mortality rates, and age of
death (web appendix).
For the cost effectiveness analysis, we used probabilistic
sensitivity analysis to propagate the joint uncertainty of
individual parameters and alternative scenario sensitivity
analysis to explore the effect of alternative model assumptions.
We repeated the microsimulation of 100 000 people 1000 times.
Costs (£ in 2010) and effects were reported in net present values,
discounting at an annual rate of 3% according to Danish practice.
Sensitivity analyses
Several potential drivers of the cost effectiveness are highly
correlated. Therefore, we specified four alternative scenarios
for the sensitivity analysis (box).
Results
Key events
Detection of aneurysms will occur regardless of screening.
However, health professionals would probably not react to small
aneurysms in the same manner as they would to large
aneurysms. Assuming that the incidental detection rate was zero
in small aneurysms and 12% per year in aneurysms of 55 mm
or more in diameter, the model predicted that 2469men per 100
000 screened would be detected with a clinically relevant
aneurysm (table 2⇓). Rescreening once after five years would
detect an additional 452 men per 100 000 initially screened,
whereas rescreening every five years for lifetime would detect
794 men per 100 000 initially screened. The number of
incidentally detected aneurysms decreased alongside systematic
screening, as the number of potentially detectable aneurysms
decreased.
Themodel estimated the number of elective surgeries to increase
from 861 to 1390 per 100 000 as a result of screening once per
lifetime. This number increased to 1496 and 1530 per 100 000,
for rescreening once and for rescreening for life, respectively.
The corresponding number of acute surgeries reduced from 610
to 382 per 100 000 after screening once and fell further to 363
and 360 per 100 000 after rescreening once and for life,
respectively. Relative risk reductions for acute surgery and
rupture associated with repeating the rescreening regimen for
lifetime were moderate because aneurysms detected later in life
seemed to be in size categories, with insignificant symptom and
rupture rates.
The rate of aneurysm related mortality reduced from 788 to 538
per 100 000 men as a result of screening and fell further to 520
and 511 per 100 000, if screening was repeated after five years
or at five year intervals for lifetime, respectively. This decrease
was the result of replacing acute surgery with elective surgery,
which is characterised by much lower mortality rates after
surgery and the prevention of ruptures leading to death before
patients reach the hospital. Non-aneurysm related mortality
represents the residual lifetime mortality and, thus, varies only
if the aneurysm related mortality occurred first. Estimated age
at aneurysm related death increased after screening was
provided, but then fell when rescreening was
provided—although fewermenwould die, relativelymore deaths
were caused by elective surgery, which decreases in the early
cycles of the model.
Table 3⇓ details the findings after rescreening. Rescreeningmen
with an aortic diameter of 25-29 mm at the initial screening led
to the detection of an additional 452 and 794men with clinically
relevant aneurysms per 100 000 initially screened, for
rescreening once after five years and at five year intervals for
life, respectively. Furthermore, most of those clinically relevant
aneurysms additionally detected were smaller than the threshold
for surgery referral; of 1851 men referred to rescreening, 31
and 50 were referred to elective surgery as a consequence of
rescreening once or for life, respectively.
Validation of model
We used the numbers of predicted key events to validate the
model against external trial observations.2Although no statistical
differences were seen between model predictions and trial
observations, we did note—as expected—that the model was
very conservative with fewer ruptures and fewer symptomatic
patients, ultimately leading to fewer aneurysm related deaths.
Therefore, the number of detected aneurysms due to screening
was lower in the model than those observed in the trial, whereas
the model predictions for rescreening were within the trial
observed levels (tables 1 to 5 in the web appendix). Overall, the
differences between model predictions and trial observations
reflected a conservative, modern model. In particular, a higher
prevalence than the overall 3.3% used to inform the model
would lead to significantly higher event rates.
The model assumed no correlations between the input
distributions for the probabilistic sensitivity analysis. This
assumption could lead to extreme predictions that would bias
results. We therefore selected a strategy to assess in detail
whether the minimum and maximum numbers of predicted
events from the probabilistic sensitivity analysis were within
plausible ranges. This seemed to be the case for all key events
(table 6 in the web appendix).
Base case cost effectiveness
Table 4⇓ shows the average costs and QALYs for the four
strategies and the probabilities for cost effectiveness, in view
of the threshold values of willingness to pay per QALY at £20
000 and £30 000, respectively. The net present value of the gain
from screening comparedwith not screeningwas 11 434QALYs
per 100 000 men screened. The corresponding gain from
screening twice was 84 QALYs, and if rescreening was repeated
for lifetime, an additional 20 QALYs would be gained.
Cost of screening was estimated at £6.34 million per 100 000
men screened, whereas the incremental costs of additional
screening were limited to about £843 000 for rescreening once
and an additional £603 000 for lifetime rescreening. Altogether,
these values represented incremental cost effectiveness ratios
of £555 for screening versus no screening, £10 013 for screening
twice versus screening once, and £29 680 for lifetime
rescreening versus screening twice. It was clearly cost effective
to screen as opposed to not screen, but the optimal choice of
rescreening strategy remained uncertain, as indicated by the
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Box: Specified scenarios for the sensitivity analysis
1) Assuming a less aggressive epidemiology, which could represent future healthcare with modern medical prevention, will ultimately
reduce the prevalence or growth rates further. Prevalence was reduced by 50% (to 1.63% overall), and growth rates were all reduced
by 25%.
2) Assuming a temporary effect of being followed for aneurysm growth on the quality of life of individuals. For patients with aneurysms
of 30-55 mm diameter, the age specific quality of life was reduced by 6%.30 When patients exited the follow-up states (figure), quality of
life was assumed to normalise to the model’s base case level.
3) The organisational design of a screening programme includes a trade-off between local provision (possibly leading to high attendance
rates) and economies of scale and scope. The present organisational design proposal seem to be more centralised (and cheaper) than
the programme currently being implemented in England. We tested the influence of a higher screening cost per person invited to
screening of £30 (€37; $47) and a higher attendance rate at the initial screening of 80%. Both levels corresponded to those observed
in the English context.6
4) The patient perspective is often neglected in screening models, as is an overall societal perspective in which production losses could
occur when workers leave their jobs to attend health programmes. We tested a societal perspective, including average transportation
costs of £7.96 per participant, private time costs of £7.85 per participant, and production loss of £2.69 per participant.31
probabilities for cost effectiveness being almost equally
distributed among the three screening strategies (with a small
overweight in favour of the rescreening strategies).
Sensitivity analyses
We tested four alternative scenarios to assess the sensitivity of
findings to alternative assumptions. None of the scenarios
significantly altered the cost effectiveness of some form of
screening compared with no screening, as the probability for
cost effectiveness of screening did not drop below 0.91 (table
5⇓). In relation to the optimal rescreening strategy, the base
case probabilities for cost effectiveness were relatively close
across the alternatives and for that reason, evenmarginal impacts
of alternative assumptions could have affected the results. In
particular, the alternative scenario 2, which tested for the
influence of a temporary reduction in quality of life associated
with enrolment in annual or biannual follow-up regimens, had
a considerable effect on the QALY gain of rescreening. For
lifetime rescreening, the QALY gain even became negative and
led to the domination of the other screening strategies.
Discussion
Principal findings
This study confirms the cost effectiveness of screening versus
not screening men for abdominal aortic aneurysms, and further
assesses the attractiveness of rescreening. At a threshold of £20
000 per QALY, rescreening once seems to be the optimal
strategy with an average incremental cost effectiveness ratio of
£10 013. However, substantial uncertainty surrounds this ratio,
and with an average incremental cost effectiveness ratio of
lifetime rescreening at £29 680, the optimal rescreening strategy
is indeterminate. For those enrolled in follow-up for aneurysms
below the surgical threshold, the alternative scenario analysis
showed that a negative effect on quality of life might alter the
attractiveness of rescreening. Clear evidence for such an effect
on quality of life is lacking, which, along with more detailed
evidence for growth rates of aneurysms, would greatly reduce
the decision uncertainty.
Strengths and limitations
This work is, to the best of our knowledge, the first to assess
the cost effectiveness of rescreening. It also considers the
current, modern world in which medical prevention has
improvedmarkedly, endovascular aortic repair is now commonly
used, symptoms are a common indication for surgery, and the
disease process is known to be more complex than a three state
model. Finally, a major strength of our methodology was the
extensive tracking of key events and subsequent microsimulation
analyses. To the best of our knowledge, this is the first example
of this technique in the abdominal aortic aneurysm literature.
The model included an effect of screening on non-aneurysm
related mortality, which has been discussed for years but not
included in previous models. The theoretical expectation that
screening should decrease non-aneurysm related mortality is
multifaceted. Firstly, the strict terminology of aneurysm related
mortality and non-aneurysm related mortality is somewhat
notional because, in practice, mortality is rarely attributable to
a single cause and therefore could bemisclassified. Furthermore,
it cannot be ruled out that screening actually leads to
prophylactic actions in patients. Regardless of the explanation,
failing to allow a potential influence of screening on the total
mortality biases the results against screening. The magnitude
of such biases was previously demonstrated after four years of
follow-up in theMulticentre Aneurysm Screening Study, where
a 2% risk reduction in mortality due to ischemic heart disease
was observed in the screening group.12
A major challenge for this type of research is that the growth
and rupture rates are key parameters for predicting the disease
course. According to European clinical guidelines,32 aneurysms
with aortic diameters of 55 mm or more are referred for surgical
evaluation once they are detected, and consequently, there are
no original studies for growth and rupture in patients with
aneurysms in the general population. The limited evidence
consists of patients with contraindications for surgery. In the
present study, we assumed a linear growth function based on
observations of smaller aneurysms and did a systematic literature
review to determine rupture rates. The linear assumption for the
growth rate could have been an overly conservative assumption
for larger aneurysms.33
An important assumption of the economic evaluation
methodology is that all feasible strategies are considered. The
present model included four strategies, although other strategies
could be relevant also—such as screening at another constant
interval than five years or screening at non-constant intervals.
The rationale for the present set-up was to contrast strategies
that have figured in recent clinical management debates while
maintaining a reasonable degree of complexity in the model.
The strategies left out of the model can be seen as intermediate
or mixed strategies, and generally the cost effectiveness of these
strategies will be expected to fall between the “raw” strategies
they are composed of.
In terms of generalisability of the present findings to the United
Kingdom, a concern would be that Danish item costs were used.
The cost effectiveness of screening was obviously driven by
costs for the screening and surgeries. To a large extent however,
the benefit of screening is that acute surgery is replaced by
elective surgery and therefore the cost difference between the
two types of surgery rather than the absolute costs is relevant
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to assess. Based on previously reported UK item costs, the
screening cost seems to be higher in the UK than in Denmark,
whereas the opposite seems to be the case for the cost difference
between the two types of surgeries. Therefore, the overall costs
of screening versus no screening could be underestimated for
the UK setting, whereas the overall costs of rescreening versus
no rescreening could be overestimated.
Comparison with other studies
The cost effectiveness of rescreening has not been studied
previously. Several studies have concluded that screening is
cost effective compared with no screening over a lifetime.5-10
This result is confirmed in the current model, which shares its
two baseline strategies with the literature, although the updated
epidemiology would lead us to expect a lower QALY gain of
screening at baseline than that seen in previous studies. On the
other hand, inclusion of the effect of screening on non-aneurysm
related mortality would lead us to expect a higher total QALY
gain. Our base case analysis estimated the total gain at about
0.11 QALYs between screening and no screening (table 4). In
other recent studies, the estimated gains ranged from 0.02 (in a
Canadian model, two Swedish models, and an English model)
to 0.05 (in a North American model), and 0.05 and 0.07 (in the
Dutch and Norwegian components of a combined model,
respectively).5-10 Differences between present and previously
estimated gains of QALYs can be attributed mainly to the effect
of screening on non-aneurysm related mortality and to increased
life expectancy, reduced prevalence of aneurysms, higher rate
for incidental detection, and a more detailed modelling of the
disease process.
Future research and policy implications
The effect of screening on quality of life is critical to the
decision scenario. Although temporary effects might be
associated withmen being offered and participating in screening,
more influential effects could stem from detection of aneurysms.
Patients with detected aneurysms eligible for referral to elective
or acute surgery could have temporary anxiety until successful
treatment is completed, whereas it has been shown that patients
return to the population norm for quality of life after treatment.34
For patients detected with smaller aneurysms, there will be a
(lengthy) follow-up period in which their quality of life could
be suppressed owing to the uncertainty about their disease
course. We conducted a systematic literature review and
identified no studies appropriately estimating the effect of such
uncertainty.22 Since our results were sensitive to reductions in
quality of life during follow-up, this research goal is important
for future studies.
Further research on growth and rupture rates would have a
positive effect on the decision uncertainty. Although most
patients are referred for surgery once an abdominal aortic
aneurysm is detected, it should be possible to observe the time
from detection to planned surgery, optimally on a national scale
and in a healthcare system in which the waiting time is
significant. In addition, the probabilistic modelling framework
allows for analysis of the value of reducing the uncertainty
surrounding particular parameters, which can help inform future
research priorities, since it was not a formal part of the present
analysis.35
This study has policy relevance for two different scenarios. In
Denmark, where no national guidance has been issued, it
suggests that there is a high probability that screening will be
cost effective. In England and Scotland, where screening is
currently being implemented, this study supports further
consideration of rescreening, at least once.
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Tables
Table 1| Parameter estimates
SourceDistribution*MeanDescription
VIVA/Viborg trials2,21
Dirichlet (94.11; 2.64; 2.71; 0.22; 0.12; 0.08;
0.06; 0.06)3.3Prevalence or disease distribution (%)
Attendance (%)
—Beta (24615,18378)75At initial screening
Beta (286, 248)87At rescan
Beta (169, 150)89At follow-up
Danish vascular registryBeta (5146, 2122)41Patients undergoing endovascular repair (%)
Mortality risk of surgery (%)
—Beta (1689, 50)3.0Elective repair
—Beta (304, 26)8.6Acute repair
—Beta (832, 322)39Acute repair after rupture
Patients with symptoms (%)
—Beta (1472, 2)0.150-54 mm
Beta (1472, 20)1.455-59 mm
Beta (1472, 22)1.560-69 mm
Beta (1472, 25)1.770-79 mm
Beta (1472, 70)4.8≥80 mm
Vardulaki et al 2002,18 Lindholt et al
2005,28 Scott et al 200529
Beta (487, 40)8.2Contraindication surgical repair (%)
Growth to next state (annual rate)
VIVA/Viborg trials2,21Beta (648, 48)0.0725-29 mm
—Beta (363, 33)0.0930-49 mm
Assumption based on extrapolation of
data from VIVA/Viborg trials2,21
Fixed0.6250-54 mm
—Fixed0.6755-59 mm
—Fixed0.3960-69 mm
—Fixed0.4470-79 mm
Rupture (annual rate)
Lederle et al 2002,24 Brown et al
200323
Beta (607, 6)0.0150-54 mm
Beta (62, 6)0.1055-59 mm
Beta (130, 14)0.1160-69 mm
Beta (73, 9)0.1270-79 mm
Beta (57, 22)0.39≥80 mm
Danish vascular registry, VIVA/Viborg
trials,2,21Danish national patient registry
Beta (1977, 232)12Incidental detection of ≥55 mm (%)
Danish vascular registry, Danish
national death-cause registry
Beta (6954, 3148)45Reaching hospital alive with rupture (%)
Costs (£ in 2010)
Lindholt et al 2010,2 Lindholt and
Sørensen 201026
Gamma (4, 0)17 377Endovascular repair
Gamma (248, 1)205Follow-up scan
Gamma (10, 0)19 778Open acute repair
Gamma (4, 0)25 733Open acute repair after rupture
Gamma (146, 0)11 108Open elective repair
Gamma (400, 20)20Screening per invitee
Excess mortality (odds ratio)
Danish vascular registry, VIVA/Viborg
trials,2,21 Danish national mortality
statistics
Fixed1.4630-49 mm
Fixed1.7050-54 mm
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Table 1 (continued)
SourceDistribution*MeanDescription
Fixed2.15>55 mm
Fixed2.57Inoperable aneurysm
Søgaard et al 201122Normal (0.98, 0.02)0.98Reduced non-AAA related mortality in screened
men (odds ratio)
Lindholt and Norman 201127Normal (0.37, 0.14)0.37Reduced postelective mortality in screened men
(odds ratio)
AAA=abdominal aortic aneurysm; mm=aortic diameter in millimetres.
*Values refer to prevalence (Dirichlet distribution); the number surveyed and the number of events (beta distribution); the shape and the scale of the distribution
(gamma distribution); and the mean and standard deviation (normal distribution).
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Table 2| Predicted numbers of key events under four alternative strategies for the management of abdominal aortic aneurysms (AAA). Data
are number or percentage unless stated otherwise
Relative risk reduction (%)No of events per 100 000 men
Lifetime screening
v screening twice
Screening twice v
screening once
Screening once v
no screening
Lifetime
screeningScreening twiceScreening onceNo screening
Detection
−8−4−31569618646934Incidental
Not applicableNot applicableNot applicable2469246924690By screening
Not applicableNot applicableNot applicable79445200By rescreening
814234383235393115934Total
Elective surgery
4566658632604364Endovascular
11058872864786497Open
2861153014961390861Total
Acute surgery
−1−3−38294297305492For rupture
0−14−35666677118For symptoms
−1−5−37360363382610Total
−1−4−336826927191069Rupture
Mortality
−2−3−32511520538788AAA related
00099 48699 47799 45999 212Non-AAA related
00099 99799 99799 997100 000Total
Age at death (years)
Not applicableNot applicableNot applicable74.3074.3774.3373.50AAA related
Not applicableNot applicableNot applicable81.0981.0981.0980.92Non-AAA related
Not applicableNot applicableNot applicable81.0681.0581.0580.86Total
Predictions based on microsimulation of 100 000 men in a Markov model.
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Table 3| Predicted numbers of key events in the rescreening strategies for men with an aortic diameter of 25-29 mm at initial screening
Relative risk reduction (%)
No of events per 100 000 men
Lifetime screeningScreening twice
6129781851Referred for rescan programme
100168Incidental detection during programme
Not applicable00Symptoms during programme
5096Rupture during programme
222622193Dead during programme
Not applicableNot applicable1644Available for rescan
8125651418Attended rescan
Findings at rescan
−35624966No growth
79653364Diameter 30-49 mm
609157Diameter 50-54 mm
615031Diameter ≥55 mm
76794452Aneurysms detected
Predictions based on microsimulation of 100 000 men in a Markov model.
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Table 4| Base case analysis
Probability of cost effectiveness*Incremental cost
effectiveness ratio (£)Costs (£ mean)QALYs (mean) £30 000£20 000
0.080.08Not applicable£23011.8474No screening
0.260.27555£29311.9618Screening once
0.320.3310 013£30111.9626Screening twice
0.340.3329 680£30811.9628Lifetime screening
*Probability that the strategy is more cost effective than the other three strategies, in view of the particular maximum willingness to pay £20 000 or £30 000 per
additional quality adjusted life year.
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Table 5| Results of alternative scenario analysis
Probability of cost effectiveness*Incremental cost
effectiveness ratio (£)Costs (£ mean)QALYs (mean) £30 000£20 000
Scenario 1 (reduced prevalence and growth rates)
0.090.09Not applicable9611.9280No screening
0.310.3235413412.0375Screening once
0.310.3111 43513812.0378Screening twice
0.290.2938 81414012.0379Lifetime screening
Scenario 2 (negative effect on quality of life while enrolled in follow-up)
0.080.09Not applicable23011.8474No screening
0.390.4058029311.9568Screening once
0.320.3288 29230111.9569Screening twice
0.210.20Dominated strategy†30811.9567Lifetime screening
Scenario 3 (local provision (higher attendance rate and programme costs))
0.090.09Not applicable22811.8502No screening
0.240.2556529211.9638Screening once
0.300.31854830111.9647Screening twice
0.370.3522 74430711.9650Lifetime screening
Scenario 4 (societal costing perspective)
0.070.07Not applicable23011.8473No screening
0.260.2666830711.9621Screening once
0.290.3010 56031511.9629Screening twice
0.380.3724 37032211.9631Lifetime screening
*Probability that the strategy is more cost effective than the other three strategies, in view of the particular maximum willingness to pay £20 000 or £30 000 per
additional QALY.
†One or more alternative strategies was less expensive and more effective.
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Figure
Fig 1 Markov model for the course of abdominal aortic aneurysms. Diagram is a simplified presentation of the disease
history and relevant modalities for intervention. Eight boxes to the left of the diagram=starting states; numbers=abdominal
aortic diameter (mm). Men either remain in their current state or move to a neighbouring state, following the connecting
lines. Detection of aneurysms can be incidental or follow on from systematic screening
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